Overview and Scope
Pharmaceutical intermediates refer to chemical compounds or substances that are used in the synthesis and production of active pharmaceutical ingredients (APIs) or drug substances. It is used by pharmaceutical companies, and research institutions in the development and production of a wide range of drugs and therapeutic products.
Sizing and Forecast
The pharmaceutical intermediates market size has grown strongly in recent years. It will grow from $31.33 billion in 2023 to $33.59 billion in 2024 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to chemical synthesis advancements, drug development evolution, market demand and growth, research and development, regulatory compliance.
The pharmaceutical intermediates market size is expected to see strong growth in the next few years. It will grow to $43.01 billion in 2028 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to biopharmaceutical innovation, precision medicine development, green chemistry initiatives, customized intermediates, pharmaceutical outsourcing trends. Major trends in the forecast period include continuous flow chemistry, increased automation and robotics, application of nanotechnology, biocatalysis and enzyme engineering, strategic supply chain management.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/pharmaceutical-intermediates-global-market-report
The pharmaceutical intermediates market covered in this report is segmented –
1) By Product: Chemical Intermediate, Bulk Drug Intermediate, Other Products
2) By Category: Branded Drug Intermediate, Generic Drug Intermediate
3) By Application: Analgesics, Anti-Infective Drugs, Cardiovascular Drugs, Oral Antidiabetic Drugs, Antimicrobial Drugs, Other Applications
4) By End-User: Biotech And Pharma Companies, Research Institutions, Other End-Users
North America was the largest region in the pharmaceutical intermediates market in 2023. The regions covered in the pharmaceutical intermediates market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=11948&type=smp
Major Driver Impacting Market Growth
The rise in the prevalence of chronic diseases is expected to propel the growth of the pharmaceutical intermediates market going forward. Chronic diseases refer to a sickness or condition that typically lasts three months or longer and has the potential to worsen over time. The rise in chronic diseases is mostly driven by the aging population, lifestyle changes, rapid urbanization, and lack of preventive measures, where pharmaceutical intermediates play a crucial role in the development and production of medications used to manage chronic diseases. For instance, in March 2022, according to the National Institute of Health, a US-based medical research agency, the prevalence of chronic kidney disorders will be 13.4%. Additionally, it is projected that between 4.902 and 7.083 million individuals will require renal replacement therapy due to end-stage kidney disease (ESKD). The utilization of accurate pharmaceutical intermediates can play a significant role in mitigating the increasing prevalence of chronic conditions. Therefore, the rise in the prevalence of chronic diseases is driving the growth of the pharmaceutical intermediates market.
Key Industry Players
Major companies operating in the pharmaceutical intermediates market report are BASF SE, Sanofi SA, Thermo Fisher Scientific Inc, Meck KGaA, Dishman Carbogen Amcis Ltd, Evonik Industries AG, Arkema Inc., Lonza Group AG, Wuxi AppTec co. Ltd, Aurobindo Pharma Lmited., Lianhe Chemical Technology Co. Ltd., Cambrex Corporation, Vertellus Holdings LLC., Hovione LLC, Hikal Ltd., Codexis Inc., Aceto Corporation, Interchem Corporation, Midas Pharma GmbH, Arbiom, Dextra Laboratories Ltd., A. R. Life Sciences, Ingenza Ltd, Chiracon GmbH, Dyadic International Inc., Elam Pharma Pvt Ltd, Yin-sheng Bio-tech Co. Ltd., Green Vision Life Sciences, Sibylla Biotech s.r.l., Pfizer CentreOne
The pharmaceutical intermediates market report table of contents includes:
1. Executive Summary
2. Pharmaceutical Intermediates Characteristics
3. Pharmaceutical Intermediates Trends And Strategies
4. Pharmaceutical Intermediates – Macro Economic Scenario
5. Global Pharmaceutical Intermediates Size and Growth
…..
32. Global Pharmaceutical Intermediates Competitive Benchmarking
33. Global Pharmaceutical Intermediates Competitive Dashboard
34. Key Mergers And Acquisitions In The Pharmaceutical Intermediates
35. Pharmaceutical Intermediates Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
